Liliana Maruri Avidal is a scientist with over 14 years of experience in virology, molecular and cell biology, gene therapy and oncolytic viruses. Her research has focused on discovering viral protein functions and interactions, gene therapy and oncolytic viruses in both academia and industry.
Dr. Maruri Avidal completed her postdoctoral training at the prestigious laboratory of Dr. Bernard Moss at the National Institutes of Health (NIH), where she tackled one of the most controversial topics in the poxvirus field with her studies exploring the origin of the first viral membrane for the morphogenesis of poxvirus. She was awarded a NIH postdoctoral fellowship and was a finalist in the Salzman abstract competition at the NIH. With this work, she has produced over 15 publications and presentations.
Dr. Maruri Avidal has worked in the oncolytic virus and gene therapy industry as Director of Research and Bioanalytics. After the M&A of leading oncolytic vaccinia virus company Jennerex Biotherapeutics with a Korean biotech company (Sillajen), she led R&D and analytical teams to generate product designs, preclinical models and analytical assays for product release testing and clinical trial PK/PD assays for novel oncolytic viruses. At 4D Molecular Therapeutics, a gene therapy company with a robust discovery platform called Therapeutic Vector Evolution, she worked with adeno-associated virus (AAV). She designed proof of concept studies, discovered new antibody-evading AAV variants and developed cell-based assays for product testing.
After graduating with honors in biology at the National Autonomous University of Mexico (UNAM), Dr. Maruri Avidal went on to obtain a PhD in Biochemistry from the Biotechnology Institute UNAM. Her doctoral studies, which were awarded a fellowship from the Mexican National Council on Science and Technology (CONACyT), focused on the discovery and characterization of novel mechanisms involved in the viral replicative cycle.